These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease. Choi H; Kim SY; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin S; Shin SJ; Daley CL; Koh WJ Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739795 [TBL] [Abstract][Full Text] [Related]
3. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report. Kim SY; Shin SJ; Jeong BH; Koh WJ BMC Infect Dis; 2016 May; 16():207. PubMed ID: 27188784 [TBL] [Abstract][Full Text] [Related]
4. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Koh WJ; Stout JE; Yew WW Int J Tuberc Lung Dis; 2014 Oct; 18(10):1141-8. PubMed ID: 25216826 [TBL] [Abstract][Full Text] [Related]
6. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792 [TBL] [Abstract][Full Text] [Related]
7. The treatment of rapidly growing mycobacterial infections. Kasperbauer SH; De Groote MA Clin Chest Med; 2015 Mar; 36(1):67-78. PubMed ID: 25676520 [TBL] [Abstract][Full Text] [Related]
8. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2020 Jun; 6(6):CD010004. PubMed ID: 32521055 [TBL] [Abstract][Full Text] [Related]
10. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Koh WJ; Jeong BH; Kim SY; Jeon K; Park KU; Jhun BW; Lee H; Park HY; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Kim H; Kwon OJ Clin Infect Dis; 2017 Feb; 64(3):309-316. PubMed ID: 28011608 [TBL] [Abstract][Full Text] [Related]
11. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study. Henriette Zweijpfenning SM; Chiron R; Essink S; Schildkraut J; Akkerman OW; Aliberti S; Altenburg J; Arets B; van Braeckel E; Delaere B; Gohy S; Haarman E; Lorent N; McKew G; Morgan L; Wagner D; van Ingen J; Hoefsloot W Chest; 2022 Jul; 162(1):76-81. PubMed ID: 35063454 [No Abstract] [Full Text] [Related]
12. [A pharmacologic approach to treatment of Mycobacterium abscessus pulmonary disease]. Kassegne L; Veziris N; Fraisse P Rev Mal Respir; 2024 Jan; 41(1):29-42. PubMed ID: 38016833 [TBL] [Abstract][Full Text] [Related]
13. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease. Fujiwara K; Uesugi F; Furuuchi K; Tanaka Y; Yoshiyama T; Saotome M; Ohta K; Mitarai S; Morimoto K Microbiol Spectr; 2021 Dec; 9(3):e0192821. PubMed ID: 34878300 [TBL] [Abstract][Full Text] [Related]
14. Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease. Sawka A; Burke A Clin Chest Med; 2023 Dec; 44(4):815-828. PubMed ID: 37890918 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series. Namkoong H; Morimoto K; Nishimura T; Tanaka H; Sugiura H; Yamada Y; Kurosaki A; Asakura T; Suzuki S; Fujiwara H; Yagi K; Ishii M; Tasaka S; Betsuyaku T; Hoshino Y; Kurashima A; Hasegawa N BMC Infect Dis; 2016 Aug; 16():396. PubMed ID: 27506679 [TBL] [Abstract][Full Text] [Related]
17. Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series. Duah M; Beshay M Int J Infect Dis; 2022 Sep; 122():953-956. PubMed ID: 35798234 [TBL] [Abstract][Full Text] [Related]
18. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. Park J; Cho J; Lee CH; Han SK; Yim JJ Clin Infect Dis; 2017 Feb; 64(3):301-308. PubMed ID: 28011609 [TBL] [Abstract][Full Text] [Related]
20. [Progress in the treatment of Mycobacterium abscessus pulmonary disease]. Cui XC; Li Q; Zhou M Zhonghua Jie He He Hu Xi Za Zhi; 2021 Mar; 44(3):257-260. PubMed ID: 33721940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]